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The FcγR system comprises both activating and 
inhibitory receptors, and the balance of these two 
types of receptors determines the outcome of 
immune complex (IC)–mediated infl  ammation, 
immunity, and antibody-based immunotherapy 
(1). Altering this balance by using a selective 
blocking antibody against the human inhibitory 
FcγRIIB receptor in the presence of activating Ig 
ligands in human plasma leads to enhanced gener-
ation of antitumor T cell responses (2). Mice defi  -
cient in the inhibitory FcγR FcγRII also show 
enhanced T cell immunity to model antigens (3). 
However, the mechanisms by which activating 
FcγRs mediate maturation of human DCs and en-
hance adaptive immunity remain to be clarifi  ed.
IFNs are pleiotropic cytokines with potent 
antiviral, antitumor, growth suppressive, and 
immunomodulatory properties (4). The cellu-
lar eff  ects of both type I (IFN-α and -β) and 
type II (IFN-γ) IFNs are mediated via activa-
tion of the STAT family of transcription factors 
and downstream activation of a distinct set of 
“IFN response genes” (IRGs) (5). IFNs play an 
important role in the regulation of both innate 
and adaptive immunity (6). For example, IFNs 
play a critical role in T cell–dependent anti-
body responses to antigens delivered with the 
classical complete Freund’s adjuvant, DNA vac-
cines, and immunostimulatory DNA (7–9), and 
they promote the induction of cytotoxic T cells 
in vivo (10, 11). IFN-mediated signaling path-
ways also play an important role in immune 
surveillance and protection from tumors (12). 
Dysregulation of IFN signaling has been ob-
served in patients with several autoimmune dis-
eases (6, 13). Therefore, pathways that regulate 
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The ability of dendritic cells (DCs) to activate immunity is linked to their maturation status. 
In prior studies, we have shown that selective antibody-mediated blockade of inhibitory 
Fc𝗄RIIB receptor on human DCs in the presence of activating immunoglobulin (Ig) ligands 
leads to DC maturation and enhanced immunity to antibody-coated tumor cells. We show 
that Fc𝗄 receptor (Fc𝗄R)–mediated activation of human monocytes and monocyte-derived 
DCs is associated with a distinct gene expression pattern, including several infl  ammation-
associated chemokines, as well as type 1 interferon (IFN) response genes, including the 
activation of signal transducer and activator of transcription 1 (STAT1). Fc𝗄R-mediated 
STAT1 activation is rapid and requires activating Fc𝗄Rs. However, this IFN response is 
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mediated DC maturation. These data suggest that the balance of activating/inhibitory 
Fc𝗄Rs may regulate IFN signaling in myeloid cells. Manipulation of Fc𝗄R balance on DCs 
and monocytes may provide a novel approach to regulating IFN-mediated pathways in 
autoimmunity and human cancer.
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IFN signaling in myeloid cells, particularly DCs, may have a 
major impact on immunity to tumors and pathogens, as well 
as autoimmunity. An important aspect of the biology of IFN 
signaling is that the level of constitutive signaling in the ab-
sence of pathogens determines the strength of IFN signaling 
in response to pathogens (14). Therefore, there is a need to 
identify the factors that regulate the level of this constitutive 
or basal IFN signaling.
We show that FcγR-mediated maturation of human DCs 
is associated with a distinct pattern of gene expression. This 
includes the expression of several infl  ammation-associated 
cytokines and chemokines, and the induction of several typi-
cal IRGs. These data suggest that the balance of activating/
inhibitory FcγRs can regulate the IFN response program in 
human DCs and monocytes.
RESULTS
A distinct gene expression profi  le (GEP) of DCs treated 
with anti-Fc𝗄RIIB antibody
We have previously shown that treatment of monocyte-
  derived immature DCs (IDCs) with an anti-FcγRIIB–blocking 
antibody in the presence of Ig ligands in normal human 
plasma leads to DC maturation and enhancement of anti-
  tumor T cell immunity (2). To further characterize FcγR-
mediated enhancement of DC function, we analyzed the 
GEPs of pure populations of monocyte-derived DCs (Mo-
Dcs) from healthy donors (n = 5) using Aff  ymetrix Human 
Genome U133 Plus 2.0 microarrays. IDCs cultured in 1% 
plasma were treated for 24 h with either anti-FcγRIIB or 
isotype control antibody. To test whether FcγR-mediated 
DC maturation was distinct from other maturation stimuli, 
we also compared DCs matured using the infl  ammatory cy-
tokine cocktail (TNF-α, IL-1β, IL-6, and PGE2) that is 
commonly used in DC immunotherapy trials (15). To fi  rst 
validate the GEP data at the protein level, we compared the 
gene expression data for some of the genes associated with 
DC maturation (CD83 and CD80) with the detection of 
corresponding proteins by fl  ow cytometry (Fig. 1 A). As ex-
pected, mRNA expression, as well as protein levels of CD80 
and CD83, increased in DCs matured with the FcγRIIB 
blocking   antibody and in cytokine-matured DCs compared 
with isotype-treated IDCs. Of the 24,296 expressed genes 
on the array, 1,801 were diff  erentially regulated in DCs 
treated with anti-FcγRIIB antibody (RIIB DCs) versus 
those treated with isotype control antibody (Iso DCs). Most 
of these genes were also up-regulated in DCs matured with 
infl  ammatory cytokines (Cyt DCs), suggesting that these re-
fl  ected changes in gene expression shared with other DC 
maturation stimuli. However, we also identifi  ed a distinct set 
of 95 genes that were diff  erentially expressed only in RIIB 
DCs (Fig. 1 B and Table S1, available at http://www.jem
.org/cgi/content/full/jem.20062545/DC1). Thus, the GEP 
of RIIB DCs includes genes shared with Cyt DCs, as well 
as a distinct subset of genes specifi  cally overexpressed only 
in RIIB DCs.
Changes in type I IFN-induced genes after treatment 
with anti-Fc𝗄RIIB antibody
Interestingly, a majority of the genes expressed selectively in 
RIIB DCs were known to be induced by type I IFNs. To bet-
ter characterize the IFN-responsive genes in DCs, we treated 
IDCs (n = 3) with 1,000 U/ml of IFN-α2b and identifi  ed 167 
genes that were up-regulated by greater than fi  vefold at 24 h in 
IFN-treated DCs compared with untreated DCs (Fig. 1 C and 
Table S2, available at http://www.jem.org/cgi/content/full/
jem.20062545/DC1). Indeed, 54 of 95 genes in the RIIB DC–
specifi  c signature were IFN-inducible genes (Table S1). Up-
regulation of IFN-induced genes by anti-FcγRIIB antibody 
was not unique to DCs, but also   observed in monocytes treated 
with this antibody (Fig. 1 C). The IFN-induced genes in these 
cells included several well-known type I IFN response signature 
genes, such as IFN-α inducible (IFI) protein 27, myxovirus re-
sistance 1 (Mx1), Mx2, 2′-5′ oligoadenylate synthase, cig5, 
GIP3, IFI16, serpin E, IFI44, STAT1, and IRF-7 (Table S1). 
To validate the data for expression of IFN-induced genes in the 
microarray, the expression of two of these genes (IFI27 and 
Mx1) was also analyzed by real-time PCR, which confi  rmed 
the microarray fi  ndings (Fig. 1 D). Surprisingly, this increase in 
IRGs was not associated with an increase in the levels of any of 
the known type I IFNs themselves (IFN-α, -β, -ω, -τ, and in-
cluding newer members of the family such as IL28A, IL-28B, 
and IL-29; Fig. 1 E) and only a modest increase in IFN-γ at the 
mRNA and protein level as analyzed in the supernatants using 
Luminex (Table I). It is notable that a low level signal for one of 
the type I IFN genes (IFN-α17) was detectable by microarray 
in DCs treated with isotype control mAb, and consistent with 
this, low levels of IFN-α were also detectable in the superna-
tants by Luminex (Fig. 1 E and Table I). Importantly, however, 
treatment with anti-FcγRIIB mAb did not lead to a change in 
the expression of any of the type I IFNs when compared with 
isotype mAb-treated cells. Therefore, a distinct component of 
FcγR-mediated activation of DCs is the strong and rapid acti-
vation of IFN-induced genes without a concurrent increase in 
the expression of type I IFNs themselves.
Expression of infl  ammation-associated chemokines 
and cytokines in Fc𝗄R-matured DCs
In addition to the IFN-inducible genes, several other genes 
involved in infl  ammation were also diff  erentially up-regulated 
in RIIB DCs relative to Iso DCs or Cyt DCs. This included 
several CC chemokines (CCL2/MCP-1, CCL19, CCL3, 
CCL5/Rantes, and CCL4/MIP1β), cytokines (IL-1α), FcR, 
and complement-related genes. To validate the microarray 
data at the protein level, the DC culture supernatants were 
also analyzed for the presence of cytokines and chemokines 
by Luminex analysis. When compared with Iso DCs, RIIB 
DCs secreted greater amounts of MIP1α, IL1α, IL1β, IP10, 
IL-12p70, and CCL5/Rantes, which were also consistent with 
the microarray data (Table I and Fig. 2). Therefore, DC matura-
tion by selective signaling via activating FcγRs is characterized 
by a distinct pattern of infl  ammation-associated genes relative 
to DCs matured using infl  ammatory cytokines.JEM VOL. 204, June 11, 2007  1361
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Mechanism of Fc𝗄R-mediated induction of type 1 
IFN response
Because of the prominence of the IFN signature in RIIB 
DCs, we focused on further characterizing the mechanism 
for induction of these responses. Type 1 IFN-mediated ac-
tivation of its receptor activates Jak protein tyrosine kinases, 
which in turn phosphorylate STAT proteins, including 
STAT1 (16). Therefore, we used the detection of phosphor-
ylated STAT1 (P-STAT1) protein by fl  ow cytometry as a 
marker for IFN-induced response at a single-cell level. Treat-
ment of IDCs with the anti-FcγRIIB was associated with an 
increase in P-STAT1 detectable at 24 h after anti-FcγRIIB 
mAb treatment (Fig. 3 A). The increase in P-STAT1 observed 
in these experiments was also confi  rmed by Western blot 
analysis (Fig. 3 B). Anti-FcγRIIB–mediated up-regulation of 
P-STAT1 was not unique to DCs, but was also seen in mono-
cytes (Fig. 3 A). In prior studies, we have shown that DC 
maturation induced by anti-FcγRIIB requires the presence 
of activating Ig ligands in normal human plasma (2). Consis-
tent with this, anti-FcγRIIB enhanced P-STAT1 in DCs 
cultured in 1% plasma, but not those cultured in serum-free 
media (Fig. 3 C).
Next, we studied the eff  ects of IFN-α blockade on anti-
FcγRIIB–mediated STAT1 phosphorylation. As expected, the 
addition of IFN-α to IDCs led to an increase in P-STAT1, 
which was blocked by preincubation of DCs with IFN-α 
and IFN-α receptor (IFNAR) blocking antibodies (Fig. 4 A). 
However, preincubation with the IFN-α and IFNAR block-
ing antibodies did not abrogate the up-regulation of P-STAT1 
in anti-FcγRIIB–treated DCs (Fig. 4 B). It is notable, however, 
that although these mAbs inhibit the increase in P-STAT1 in 
response to exogenous IFN-α, they do not abolish the consti-
tutive levels of P-STAT1 (Fig. 4 A and not depicted). Similarly, 
pretreatment of monocytes with anti-IFNAR mAb inhibited 
the increase in P-STAT1 in response to exogenous IFN-α, but 
not after treatment with anti-FcγRIIB (Fig. 4 C).
As there was a mild, but detectable, increase in IFN-γ 
in the DC supernatants, we also analyzed the eff  ect of an 
IFNγ blocking mAb on anti-FcγRIIB–induced P-STAT1. 
The IFNγ blocking antibody was also unable to inhibit the 
up-regulation of P-STAT1 in anti-FcγRIIB–treated DCs 
(Fig. 4 D). Similar fi  ndings were observed in monocytes 
(unpublished data). Anti-FcγRIIB–mediated P-STAT1 up-
regulation was rapid and detectable within an hour of mAb 
treatment in both monocytes and DCs (Fig. 4 E). Together, 
these data suggest that selective engagement of activating FcγRs 
leads to rapid activation of IFN signaling without a concur-
rent increase in the expression of type I IFNs themselves.
Role of activating Fc𝗄Rs
Induction of DC maturation by anti-FcγRIIB antibody re-
quires the presence of activating Ig ligands present in normal 
Table I.  Expression of cytokines and chemokines secreted by DCs by Luminex analysis
Iso DC RIIB DC Cyt DC
RIIB DC versus Iso DC
(p-value)
RIIB DC versus Cyt DC
(p-value)
IL-1α 57.19 (29.4) 699.5 (184.4) 87.6 (80.8) <0.001 <0.001
IL-1β 11 (15.6) 668.9 (780) NE 0.071 NE
IL-2 10.2 (4.1) 14.3 (4.7) 21.9 (14) 0.120 0.170
IL-3 102.2 (16.2) 176 (56.5) 137.6 (35.5) 0.023 0.147
IL-5 0 (0) 0.0 0 (0) 0.000 0.000
IL-6 229.6 (142.6) 7941.8 (4116.4) NE 0.005 NE
IL-7 0.1 (0.2) 27 (3.8) 16.4 (12.7) 0.000 0.080
IL-8 628.1 (408.1) 10000 (0) 5727 (4992.1) <0.001 0.069
IL-10 22.5 (2.8) 1200.9 (987.5) 108.6 (111.5) 0.027 0.035
IL-12p40 40.5 (28.4) 4713.3 (5019.4) 3191 (4483.3) 0.056 0.333
IL-12p70 15.9 (16.6) 148.2 (148.5) 29 (20.1) 0.064 0.082
IL-13 8.9 (3.4) 28.9 (21.1) 39.7 (47.2) 0.055 0.345
IL-15 3.8 (7.7) 0.9 (1.8) 0 (0) 0.242 0.178
IFN-γ 116.5 (8.8) 264.2 (61.1) 198.3 (81.6) 0.002 0.122
TNF-α 5.3 (6.3) 1059.8 (911.3) NE 0.030 NE
Eotaxin 15.5 (19.2) 35 (11) 43.1 (14.5) 0.065 0.204
MCP1 1173.1 (1074) 2776.34 (2655.6) 1314.8 (1908.4) 0.153 0.203
Rantes 27.8 (16.5) 1531 (682) 264.8 (356.3) 0.002 0.008
MIP1a 710.6 (351.3) 9746.9 (388) 3067.8 (2733.7) <0.001 0.001
IP10 395.3 (185.4) 8629.8 (2364.7) 637.9 (664.9) <0.001 <0.001
IFN-α 10.2 (9.9) 10.3 (12.5) 28.9 (15.6) 0.493 0.056
IDCs (n = 4) were treated with anti-FcγRIIB antibody (RIIB DC), inflammatory cytokine cocktail (Cyt DC), or isotype control antibody (Iso DC). 24 h later, the 
culture supernatant was collected and examined for cytokines and chemokines by Luminex assay. NE, not evaluable, as these cytokines were added exogenously 
to Cyt DCs.1362  FCγ RECEPTORS ENHANCE INTERFERON SIGNALING | Dhodapkar et al.
Figure 1.  Changes in GEPs of human DCs treated for 24 h with 
isotype control antibody, anti-Fc𝗄RIIB antibody, or an infl  ammatory 
cytokine cocktail. (A) Validation of microarray. Immature monocyte–
derived DCs from healthy donors (n = 4) were treated with 20 μg/ml 
mouse IgG1 (Iso), 20 μg/ml anti-FcγRIIB blocking antibody (RIIB), or in-
fl  ammatory cytokine cocktail (IL-1β, TNF-β, PGE2, and IL-6; Cyt). 24 h 
later, some DCs from each of the three conditions were analyzed for the 
expression of DC maturation markers (CD83 and CD80) by fl  ow cytometry. 
RNA was extracted from the rest of the DCs and gene expression was 
examined using Human Genome U133 Plus 2 Affymetrix chips. These 
graphs show the changes in the expression of DC maturation markers 
(CD80 and CD83) at the level of mRNA (by microarray) and protein 
(by fl  ow cytometry). (B) Heatmap of 1,801 genes differentially expressed 
between Iso DC and RIIB DC. Day 5 immature Mo-DCs were treated with 
either 20 μg/ml mouse IgG1 (Iso DC), 20 μg/ml anti-FcγRIIB antibody 
(RIIB DC), or infl  ammatory cytokine cocktail (IL-1β, TNF-β, PGE2, and IL-6; 
Cyt DC). 24 h later, the DCs were harvested and RNA was extracted and 
analyzed using the Human Genome U133 Plus 2 Affymetrix gene array 
chips and the GeneSpring software. Genes that were marked as present 
and expressed above a raw level of 100 were included in the analysis. 
Iso DC, RIIB DC, and Cyt DC were analyzed to detect genes that were 
differentially expressed between the three groups using a parametric test 
with variance assumed equal (ANOVA) with a p-value cut off of 0.05, followed 
by the Benjamin and Hochberg false discovery rate multiple correction. 
4,759 genes were found to be differentially expressed between Iso DC, 
RIIB DC, and Cyt DC. Of these 4,759 genes, 1,801 genes were found to be 
differentially expressed in RIIB DCs compared with Iso DCs (twofold 
difference; P < 0.05). (left) The expression of these 1,801 genes in RIIB DC 
and Iso DC. (right) The expression of the same 1,801 genes in DCs treated 
with infl  ammatory cytokines (Cyt DC). The box shows a subset of 95 genes 
that are overexpressed only in RIIB DCs compared with both Iso DCs and 
Cyt DCs. Details of these genes are noted in Table S1. (C) Heat map of 
IRGs in monocytes and DCs treated with anti-FcγRIIB antibody or isotype 
control antibody. Day 5 monocyte derived IDCs (n = 3) were treated with 
IFN-α2b (1,000 U/ml) or left untreated. 24 h later, RNA was extracted and 
analyzed using the Human Genome U133 Plus2 Affymetrix chips and the 
GeneSpring software (version 7.2). 167 genes were found to be up-
regulated by more than fi  vefold in IFN-treated DCs compared with untreated 
DCs. (left) Expression of the 167 IFN-α–induced genes in DCs treated with 
IFN-α and untreated DCs (No Rx). Expression of the 167 IRGs was then 
compared in DCs (n = 5) and monocytes (n = 3) treated with anti-
FcγRIIB mAb (RIIB) or isotype control antibody (Iso). (D) Expression of two JEM VOL. 204, June 11, 2007  1363
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human plasma (2). The Mo-DCs used in these experiments 
were generated from CD14+ monocytes purifi  ed using 
immunomagnetic beads and cultured in 1% plasma. These 
DCs express higher levels of CD32, as well as CD16, com-
pared with DCs generated from plastic adherent monocytes 
(Fig. 5 A and not depicted) (17). To evaluate the role of specifi  c 
activating FcγRs, the DCs were preincubated with antibodies 
against CD16 and CD32A before blockade of CD32B. Prior 
incubation with a cocktail of antibodies against activating 
FcγRs, FcγRIIA (CD32A), and FcγRIIIA (CD16) inhibited 
anti-FcγRIIB–mediated up-regulation of DC maturation 
markers (CD80 and CD83; Fig. 5 B).
Preincubation of DCs with a cocktail of antibodies against 
both activating FcγRs (CD32a and CD16) inhibited anti-
FcγRIIB–mediated induction of P-STAT1 (Fig. 5 C). These 
antibodies also blocked anti-FcγRIIB–mediated up-regulation 
of STAT1 in monocytes (Fig. 5 D). This was also associated 
Figure 2.  Up-regulation of chemokines/cytokines in Fc𝗄R-matured 
DCs. Validation of microarray data at the protein level. Monocyte-derived 
IDCs (four different donors) were treated with 20 μg/ml anti-FcγRIIB 
antibody (RIIB DC) or 20 μg/ml isotype control antibody (mouse IgG1; Iso 
DC). 24 h later, DCs were harvested and RNA was extracted and analyzed 
using the U133 Plus2 Affymetrix chips (as in Fig. 1). The culture superna-
tant was analyzed for the expression of cytokines/chemokines by Luminex 
analysis. The graphs show the fold increase in mRNA expression (A) 
or protein secretion (B) for the cytokines and chemokines in RIIB DC 
compared with Iso DC. 
Figure 3.  Mechanism of Fc𝗄R-mediated induction of IFN response. 
(A) Up-regulation of P-STAT1 in DCs or monocytes treated with anti-
FcγRIIB mAb versus isotype control. Immature Mo-DCs (n = 8) or freshly 
isolated monocytes (n = 7) were treated with anti-FcγRIIB antibody (RIIB) 
or isotype control antibody (Iso). 24 h later, P-STAT1 expression was exam-
ined by fl  ow cytometry. The histogram shows fold change in expression of 
P-STAT1 in anti-FcγRIIB antibody–treated versus isotype control antibody–
treated cells. *, P < 0.05. (B) Western blot confi  rmation of up-regulation 
of phosphorylated STAT1 in DCs treated with anti-FcγRIIB antibody 
versus isotype control antibody. Monocyte-derived IDCs were treated with 
isotype control mouse IgG1 antibody (Iso) or anti-FcγRIIB antibody (RIIB). 
24 h later, the DCs were harvested and the protein was analyzed on a 
7.5% polyacrylamide gel to detect the presence of phosphorylated STAT1. 
(left) Representative of four separate experiments. (right) The summary of 
data for quantitative densitometry. Value for P-STAT1 was fi  rst normalized 
against data for α-tubulin in that sample, before comparison between 
RIIB DCs and Iso DCs. Data shown are the summary of four separate 
  experiments. *, P < 0.05. (C) Expression of phosphorylated STAT1 (P-STAT1) 
in DCs treated with anti-FcγRIIB antibody or isotype control antibody in 
serum-free medium compared with 1% plasma. Immature monocyte–
derived DCs were treated with anti-FcγRIIB antibody (RIIB DC) or isotype 
control antibody (Iso DC) in serum-free medium or in medium supple-
mented with 1% human plasma. 24 h later, the expression of P-STAT1 
was examined by fl  ow cytometry. Data are representative of three similar 
experiments. Data represent the mean ± the SD.
IFN-induced genes (Mx1 and IFI27) in DCs treated with anti-FcγRIIB mAb 
or isotype control was analyzed by TaqMan, and expression data was 
compared with the data obtained by microarray analysis. RNA from two 
donors (used in the microarray analysis) was analyzed by TaqMan to ver-
ify the expression of two IFN-induced genes (Mx1 and IFI27). The fi  gure 
shows the Taqman expression data compared with the expression data 
obtained by microarray analysis. (E) Expression of type I IFNs by micro-
array. Gene expression data obtained from DCs treated with either isotype 
antibody or anti-FcγRIIB antibody, as in Fig. 1 B, was analyzed for the 
expression of type I IFN genes. The histogram shows the mean ± the SD 
for the mRNA expression from four different donors. Table S1 is available 
at http://www.jem.org/cgi/content/full/jem.20062545/DC1. 
with down-regulation of the IFN-induced genes on micro-
array analysis (unpublished data). To examine the relative 
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mAb-mediated STAT1 up-regulation, we also evaluated the 
eff  ect of individual blockade of FcγRIIIA and FcγRIIA on up-
regulation of P-STAT1. Blockade of FcγRIIIA on mono-
cytes with clone 3G8 led to greater inhibition of P-STAT1 
up-regulation, compared with FcγRIIA blocking antibody 
(clone IV.3), suggesting that FcγRIIIA may be the major ac-
tivating FcγR contributing to STAT1 phosphory  lation in 
monocytes (Fig. 5 E). Aggregation of FcγRs bearing ITAM 
motifs leads to the activation of Syk family of tyrosine kinases 
(18, 19). Tassiulas et al. recently demonstrated that Syk and 
associated adaptor proteins can enhance IFN-α signaling by 
direct phosphorylation of STAT1 (20). Consistent with this, 
pretreatment of DCs with a Syk inhibitor, piceatannol, inhibited 
the up-regulation of P-STAT1, as well as maturation induced 
by anti-FcγRIIB (Fig. 5 F). Collectively, these data suggest that 
the signals via activating FcγRs contribute to the induction of 
P-STAT1 under these experimental conditions.
Role of STAT1 in Fc𝗄R-mediated DC maturation
Prior studies have shown that type I IFNs can mediate pheno-
typic and functional activation of human DCs. We hypo-
thesized that the activation of IFN pathway/STAT1 by 
anti-FcγRIIB mAb may be essential for FcγR-mediated DC 
maturation. To test this directly, we knocked down STAT1 
protein in IDCs using RNAi. IDCs were electroporated with 
STAT1 siRNA or nontargeted control siRNA. The expres-
sion of STAT1 protein was markedly inhibited at 48 and 72 h 
in DCs treated with STAT1 siRNA, but not in nontargeted 
control siRNA (Fig. 6 A). At 72 h after treatment with 
siRNA, DCs were treated with anti-FcγRIIB or isotype 
control mAb. DCs treated with STAT1 siRNA showed 
  decreased up-regulation of maturation markers (CD80 and 
CD83; Fig. 6, B and C). However, these DCs were capable 
of maturation in response to an infl  ammatory cytokines cock-
tail. Therefore, STAT1 plays an important role in FcγR-
mediated induction of DC maturation.
DISCUSSION
ICs and antibodies play an important role in autoimmune 
and allergic infl  ammation and in protection from infectious 
pathogens (21). The immunologic eff  ects of ICs depend on 
the balance between activating and inhibitory FcγRs, includ-
ing in DCs (3, 21). These data demonstrate that manipulating 
this balance via antibody-mediated blockade of inhibitory 
FcγRIIB in the presence of activating ligands in the human 
Figure 4.  Induction of IFN response by anti-Fc𝗄RIIB antibody is 
not inhibited by blocking antibodies against IFN-𝗂 and IFN-𝗄. (A) Up-
regulation of P-STAT1 by exogenous IFN-α is blocked by antibodies 
against IFN-α. Monocyte-derived IDCs were either left untreated (DC−) 
or treated with IFN-α2b (1,000 U/ml intron A). The DCs were either 
treated with a combination of blocking antibodies against IFN-α, as well 
as IFNAR (αIFNAR; both at 10 μg/ml) or with their isotype control anti-
bodies (Isotype; mouse IgG1 and mouse IgG2a, respectively; both at 
10 μg/ml) for 45 min before treatment with IFN-α. The DCs were analyzed 
for their expression of P-STAT1 by fl  ow cytometry. Gray area of the histo-
gram shows staining of the DCs with isotype control (Mouse IgG2a) for 
P-STAT1 antibody. The graph represents one of two similar experiments. 
(B) Effect of blocking antibodies against IFN-α on anti-FcγRIIB–mediated 
induction of P-STAT1. Monocyte-derived IDCs were treated with anti-
FcγRIIB antibody (5 μg/ml RIIB) or mouse IgG1 isotype control anti-
body (Iso). DCs treated with anti-FcγRIIB antibody were either treated 
with blocking antibodies against IFN-α and IFNAR (10 μg/ml RIIB + 
αIFNa+αIFNAR) or isotype control antibody (RIIB + Isotype; 10 μg/ml 
mouse IgG2a and 10 μg/ml IgG1, respectively) for 45 min before the 
  addition of anti-FcγRIIB antibody. 24 h later, fl  ow cytometry was performed 
to examine the expression of P-STAT1. Some DCs were also stained with 
mouse IgG2a, which is isotype control for the P-STAT1 antibody. One of 
two similar experiments. (C) Effect of anti-IFNAR blocking antibody on 
anti-FcγRIIB–mediated induction of P-STAT1. Freshly isolated PBMCs 
were treated with IFN-α2b (1,000 U/ml intron A) or anti-FcγRIIB antibody 
and an isotype control antibody either in the presence of 20 μg/ml IFNAR 
antibody (IFNAR Ab) or isotype control antibody (mouse IgG2a). 1 h later, 
fl  ow cytometry was performed to examine the expression of P-STAT1 on 
CD14+ monocytes. Data shown are the summary of three similar experi-
ments. *, P < 0.05. Data represent the mean ± the SD. (D) IFNγ blocking 
antibodies do not inhibit the up-regulation of P-STAT1 by anti-FcγRIIB 
antibody. IDCs were treated with either anti-FcγRIIB antibody (5 μg/ml 
RIIB) or isotype control antibody (Iso). DCs treated with anti-FcγRIIB anti-
body were either treated with blocking antibodies against IFNγ and IFNAR 
(10 μg/ml RIIB + αIFNγ) or isotype control antibody (10 μg/ml RIIB + Iso-
type; mouse IgG1) for 45 min before the addition of anti-FcγRIIB antibody. 
24 h later, fl  ow cytometry was performed to examine the expression of 
P-STAT1. Some DCs were also stained with mouse IgG2a, which is 
 iso type control for the P-STAT1 antibody. The graph shows one of two 
  similar experiments. (E) Anti-FcγRIIB induced up-regulation of P-STAT1 
is rapid. Immature monocyte derived DCs (left) or monocytes (right) were 
treated with 10 μg/ml anti-FcγRIIB antibody (RIIB) or mouse IgG1 isotype 
control antibody (Iso). 1 h later fl  ow cytometry was performed to detect 
the expression of P-STAT1. Gray histogram shows staining with mouse 
IgG2a isotype control antibody for P-STAT1. The graphs show one of fi  ve 
similar experiments.JEM VOL. 204, June 11, 2007  1365
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serum has major eff  ects on gene expression and activation 
status of human monocytes and DCs. Signaling via activating 
FcγRs on DCs provides a distinct form of maturation stimu-
lus that is characterized by the expression of P-STAT1 and 
several IRGs, as well as infl  ammation-associated chemokines/
cytokines. Activation of P-STAT1 is critical to FcγR-mediated 
eff  ects on DCs, because suppression of STAT1 inhibits FcγR-
mediated DC maturation.
The fi  nding that FcγR signaling can alter the expression 
of IRGs has implications for the regulation of IFN signaling 
in FcγR-expressing myeloid cells. Typically, induction of 
IFNs in response to viral pathogens is mediated by cyto-
solic receptors (e.g., RIG1 and MDA5) in infected cells, 
or endosomal receptors (e.g., Toll receptor family) in antigen-
  presenting cells (22). Downstream signaling in response to IFNs 
and activation of Jak–STAT pathway is also highly regulated 
(e.g., by the PIAS or SOCS family of proteins) (23). How-
ever, studies by Taniguchi et al. have shown that the strength 
of IFN response to pathogens depends on the level of consti-
tutive signaling in the absence of pathogens (14). Our data 
suggest that the balance of activating/inhibitory FcγR signal-
ing in DCs may have a direct impact on this basal level of 
IFN signaling in myeloid cells in the absence of pathogens. 
This balance may, in principle, be altered both in the context 
of specifi  c FcγR polymorphisms, or the ability of ICs to bind 
activating versus inhibitory FcγRs.
Aggregation of FcγRs bearing ITAM motifs leads to the 
activation of Syk family of tyrosine kinases (18, 19). Tassiulas 
et al. recently showed that Syk and associated adaptor pro-
teins can enhance IFN-α signaling by direct phosphorylation 
of STAT1 (20). Our data extend these observations and sug-
gest a role for activating FcγRs on human monocytes and 
Figure 5.  Role of activating Fc𝗄Rs in the FcR-mediated DC matu-
ration and induction of P-STAT1. (A) Expression of FcγRI, RIIA, RIIB, 
and RIIIA on DCs generated from CD14+ monocytes by fl  ow cytometry. 
Day 5 monocyte-derived IDCs were examined for the expression of FcγR1, 
FcγRIIA, FcγRIIB, and FcγRIII by fl  ow cytometry. The area in gray repre-
sents staining with isotype control antibodies. Figure represents one of six 
similar experiments. (B) Down-regulation of anti-FcγRIIB antibody in-
duced DC maturation by blocking antibodies against activating FcγR. IDCs 
(n = 4) were treated with isotype control antibody or anti-FcγRIIB anti-
body either with blocking antibodies against CD32A and CD16 antibody 
(αCD32A + αCD16; clone IV.3 and 3G8, both at 10 μg/ml) or their 
isotype control antibodies (Isotype; mouse IgG2a and IgG1, respectively). 
24 h later, the expression of CD80 and CD83 was monitored by fl  ow cy-
tometry, and the double-positive cells were used to assess DC maturation. 
Change in maturation between isotype-treated and anti-FcγRIIB–treated 
DCs was considered as 100%. The figure shows the percentage of 
  decrease in maturation of DCs treated with blocking antibodies against 
the activating FcγR (CD32A and CD16). Data are a summary of four similar 
experiments. *, P < 0.05. (C and D) Down-regulation of anti-FcγRIIB anti-
body induced P-STAT1 by blocking antibodies against activating FcγRs. 
IDCs (C) or PBMCs (D) were treated with mouse IgG1 isotype control anti-
body (Isotype) or anti-FcγRIIB antibody (RIIB). Some of the DCs and 
PBMCs treated with anti-FcγRIIB antibody were pretreated with blocking 
antibodies against CD32A and CD16 (αCD32A + αCD16; clone IV.3 and 
clone 3G8, respectively, both 10 μg/ml) or isotype control antibodies for 
the CD32A and CD16 blocking antibodies (mouse IgG2a and mouse IgG1, 
respectively; 10 μg/ml) for 45 min. Expression of P-STAT1 on CD11c+ DCs 
or CD14+ monocytes was examined by fl  ow cytometry. Data are repre-
sentative of four similar experiments for DCs and three for monocytes. 
(E) PBMCs were treated with MIgG1 isotype control antibody or anti-
FcγRIIB antibody. Some of the anti-FcγRIIB–treated PBMCs were pretreated 
with blocking antibody to CD16 (3G8), CD32A (IV.3), or a combination of 
blocking antibodies against CD16 and CD32A (3G8 + IV.3) or their iso-
type control antibodies (mouse IgG1 and mouse IgG2a, respectively; Iso). 1 h 
later, the expression of P-STAT1 in CD14+ monocytes was analyzed by 
fl  ow cytometry. The change in expression of P-STAT1 between MIgG1-
treated cells and anti-FcγRIIB–treated cells was considered as 100%. The 
fi  gure shows the percentage of decrease in this P-STAT1 phosphorylation 
by blocking antibodies against CD16 (αCD16) and CD32A (αCD32A), 
either alone or in combination (αCD16 + αCD32A). The histogram shows 
the summary of experiments on three separate donors (*, P < 0.05). 
(F) Inhibition of Syk tyrosine kinase abrogates anti-FcγRIIB induced up-
regulation of P-STAT1. Immature Mo-DCs were treated with medium alone 
(medium) or Syk tyrosine kinase inhibitor piceatannol (PICE) at 5 μmol 
concentration. 30 min later, the DCs were treated with either anti-FcγRIIB 
antibody or isotype control mouse IgG1 antibody (MIgG1). 24 h later, the 
DCs were analyzed for their P-STAT1 expression and maturation (CD80 
and CD83) by fl  ow cytometry. Change in expression of P-STAT1, as well as 
maturation between MIgG1-treated cells and anti-FcγRIIB–treated cells, 
was considered as 100%. The histogram on the left shows the percentage 
of decrease in this P-STAT1 phosphorylation by piceatannol treatment. 
The histogram on the right shows the percentage of decrease in DC 
maturation by piceatannol treatment. The graphs are a summary 
of experiments on three separate donors (*, P < 0.05). Data represent 
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DCs in enhancing the expression of IRGs. Further studies are 
needed to evaluate this pathway.
 Importantly, the FcγR-mediated induction of IRGs was 
not associated with a detectable increase in the expression of 
any of the type I IFNs, and it did not require the addition of 
exogenous IFNs to these cultures. Blocking mAbs against 
IFNAR and IFN-α, which block the increase in P-STAT in 
response to exogenous IFN-α, also fail to block this response. 
The induction of STAT1 phosphorylation by anti-FcγRIIB 
was rapid and detectable within 1 h of treatment with anti-
FcγRIIB blocking antibodies, which also argues against the 
IFN signature being caused by synthesis of new IFNs. It is 
also important to emphasize that the IFN signature is not 
  observed in DCs treated specifi  cally with infl  ammatory cyto-
kines (Cyt DCs). Collectively, these data suggest a novel link 
between FcγR signaling and IFN response in human DCs 
and monocytes. However, it is important to note that low 
levels of type I IFNs (IFN-α17) were expressed in control 
DCs and detectable in supernatants (although unchanged in 
response to anti-FcγRIIB mAb). Furthermore, the IFNAR 
blocking antibodies were unable to block the constitutive 
level of P-STAT1. Therefore, the observed eff  ects are consis-
tent with the ability of FcγR-mediated signals to modify the 
constitutive IFN signaling in these cells (14).
The nature of specifi  c activating FcγRs and other signals 
that are important for regulating IFN signaling in DCs re-
quires further study and may be cell/tissue type specifi  c. In 
our experiments, the signal was delivered via both FcγRIIIA 
and FcγRIIA. Recent studies have shown that FcγRIIIA is 
expressed on distinct subsets of human monocytes and DCs 
(24, 25), although their functional signifi  cance remains to be 
clarifi  ed. Polymorphisms in both FcγRIIA and FCγRIIIA 
may therefore have a signifi  cant impact on immune activation 
mediated by ICs and antibody-coated tumor cells (26, 27).
Selective blockade of inhibitory FcγR signaling on DCs 
also leads to the up-regulation of several other genes not in 
the type I IFN pathway, but implicated in autoimmune and 
allergic infl  ammation. These include several CC chemokines, 
such as CCL5, CCL4, and CCL3, which were documented 
at both mRNA and protein level. Expression of these chemo-
kines may allow FcγR-matured DCs to attract several im-
mune cells, including T cells, monocytes, DCs, and eosinophils, 
which play an important role in infl  ammation (28).
These data also have several clinical implications. Dys-
regulation of FcγR signaling may contribute to the altered 
IFN signaling observed in several autoimmune states (13, 27). 
Therefore, either restoring the FcγR balance or inhibiting 
STAT1 may help suppress immune activation in lupus. In-
deed, recent studies have shown that only small changes in 
inhibitory FcγR can have major eff  ects on immunopathology 
in lupus (29). Altered IFN signaling and STAT1/STAT3 ratio 
in myeloid DCs and other myeloid cells has also been impli-
cated in the loss of protective antitumor immunity and im-
mune surveillance in several models (12, 30, 31). Interestingly, 
recent studies have also implicated a more direct role for ICs 
in promoting tumor growth (32). Our observations may serve 
to link these fi  ndings together. Manipulating FcγR balance 
on tumor-infi  ltrating DCs (e.g., via anti-FcγRIIB antibodies) 
may be of value as a general approach to regulate endogenous 
antitumor immunity. Modulation of IFN signaling may also 
contribute to the effi   cient induction of T cell immunity ob-
served by selectively targeting ICs or antibody-coated tumor 
cells to activating FcγRs on human and murine DCs (2, 3, 
33, 34); therefore, manipulating the FcγR balance may also 
be targeted for improving the effi   cacy of antibody-based 
therapy (35) or DC-based immunotherapy of cancer (36).
Figure 6.  Fc𝗄R-mediated DC maturation can be inhibited by 
STAT1 knockdown. (A) Day 4 IDCs were electroporated with 10 μg 
of STAT1 siRNA (STAT1) or nontargeting siRNA (Control). Some DCs were 
cultured without electroporation (No electr). The DCs were harvested 
48 and 72 h after electroporation, and a Western blot was performed to 
detect total STAT1 protein. Data are representative of two separate experi-
ments. (B and C) DCs were harvested 72 h after electroporation with 
either STAT1 siRNA or nontargeting control siRNA. Some nonelectropor-
ated DCs were also harvested. The DCs were treated with anti-FcγRIIB 
antibody or isotype control antibody. Some of the DCs electroporated with 
STAT1 siRNA were also treated with the infl  ammatory cytokine cocktail. 
24 h later, DC maturation was determined by examining the expression 
of CD80, CD83, and CD11c by fl  ow cytometry. (B) Summary of data 
in four independent experiments (mean ± the SD; *, P < 0.05). (C) Data 
from a representative experiment.JEM VOL. 204, June 11, 2007  1367
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MATERIALS AND METHODS
Generation of DCs. PBMCs were isolated from blood of healthy donors 
via density gradient centrifugation using Ficoll-Hypaque (GE Healthcare). 
CD14+ cells were obtained using CD14 microbeads and LS columns (Miltenyi 
Biotec) and used to generate DCs. DCs were generated by culturing CD14+ 
cells in RPMI-1640 medium with l-glutamine ( Mediatech) supplemented 
with 1% single donor plasma, gentamicin (20 μg/ml; BioWittaker), and 
0.01 M Hepes (Cambrex). For some experiments, DCs were cultured in 
AIM-V serum free medium (Invitrogen). 20 ng/ml GM-CSF (Immunex) and 
12.5 ng/ml IL-4 (R&D Systems) were added to the culture on days 0, 2, and 4. 
On day 5 of culture, IDCs were either treated with 10–20 μg/ml anti-
FcγRIIB antibody (clone 2B6; MacroGenics), 10–20 μg/ml mouse IgG1 
isotype control (Sigma-Aldrich), or infl  ammatory cytokine cocktail (10 ng/ml 
IL-1β, 1,000 U/ml IL-6, 10 ng/ml TNF-α (all from R&D Systems), and pros-
taglandin E2 (1 μg/ml, Sigma-Aldrich). As R/H polymorphisms of the activating 
receptor CD32A can potentially impact FcR-mediated DC maturation, they 
were monitored by fl  ow cytometry using specifi  c antibodies (17, 37). All do-
nors in this study had HH/HR genotype (not depicted). Purity of the DC 
preparations was evaluated by fl  ow cytometry and was >95%. The percent-
age of contaminating NK cells was <0.1%.
Microarray analysis. IDCs on day 5 of culture (n = 5) or CD14+ mono-
cytes isolated from immunomagnetic bead selection (n = 3) were treated 
with 20 μg/ml anti-FcγRIIB mAb, isotype control (mouse IgG1 mAb), or 
infl  ammatory cytokine cocktail. After 24 h of culture, cells were pelleted in 
RLT buff  er. RNA was extracted from the DCs using the RNeasy kit (QIAGEN) 
as per the manufactures protocol. Total RNA (1–2 μg) was labeled and hy-
bridized using the Enzo T7 labeling kit (Life Sciences) on Aff  ymetrix Human 
Genome U133 Plus 2.0 microarray (Aff  ymetrix). Washing and scanning was 
done with Fluidics Station 400 and GeneChip Scanner 3000 (both from Af-
fymetrix) following the manufacturer’s protocol. Aff  ymetrix GCOS 1.2 soft-
ware was used to obtain the raw signal and present/absent gene data. Further 
analysis of the data was performed using GeneSpring software version 7.2 
(Silicon Genetics).
Data analysis of microarray data. The methodology for analysis of 
microarray data was similar to that used by Napolitani et al. (38). The micro-
array data was normalized as follows. The signal values below 0.01 were set to 
0.01. The percentile for all the measurements in each sample was calculated 
using the values for all genes not marked “absent.” Each measurement was 
divided by the 50th percentile of all measurements in that sample. Each gene 
was divided by the median of its measurements in all samples. Genes that 
were marked as present and expressed a raw level of >100 were included in 
the analysis. 29,499 genes passed this fi  lter. Gene expressions in DCs treated 
with infl  ammatory cytokines, FcγRIIB blocking antibody, and isotype con-
trol antibody were compared, and genes with statistically diff  erent expression 
between the groups based on the values of the replicates were calculated us-
ing a parametric test with variance assumed equal (ANOVA) using a p-value 
cut off   of 0.05, followed by Benjamin and Hochberg false discovery rate 
multiple-test correction. A gene list of 4,759 signifi  cant genes was obtained 
and used to determine fold changes in expression between the three diff  erent 
conditions. Of these 4,759 genes, 1,801 genes were diff  erentially regulated 
between FcγRIIB antibody-treated DCs by twofold or higher, compared 
with isotype control antibody–treated DCs. Microarray data are available 
in the National Center for Biotechnology Information Gene Expression 
Omnibus (http://www.ncbi.nih.gov/geo/) under accession no. GSE7509.
Real time PCR (TaqMan) analysis. RNA was isolated with RNeasy 
Mini kit (Qiagen) and RT-PCR was conducted with Assays-on-Demand 
primer-probe for IFI27 and Mx1 using the ABI PRISM 7700 sequence de-
tection system (both Applied Biosystems). Expression of GAPDH was moni-
tored as a housekeeping gene. Reactions were set up in triplicates using 
EZ PCR Core Reagents (Applied Biosystems) according to the manufacturer’s 
instructions with 20 ng of total RNA. Relative expression of target genes 
was calculated using the comparative threshold cycle method.
Luminex assay. Cell supernatants from 24-h DC cultures were analyzed 
for 20 cytokines and chemokines using the Protein Multiplex Immunoassay 
kit (Biosource International) as per the manufacturer’s protocol. In brief, 
Multiplex beads (Biosource) were vortexed and sonicated for 30 s, and 25 μl 
was added to each well and washed two times with wash buff  er. The samples 
were diluted 1:2 with assay diluent and loaded onto a Multiscreen BV 96-
well fi  lter plate (Millipore) with 50 μl of incubation buff  er already added to 
each well. Serial dilutions of cytokine standards were prepared in parallel and 
added to the plate. Samples were then incubated on a plate shaker at 600 rpm 
in the dark at room temperature for 2 h. The plate was applied to a Multi-
screen Vacuum Manifold (Millipore) and washed twice with 200 μl of wash 
buff  er. 100 μl of biotinylated anti–human Multi-Cytokine Reporter (Bio-
source International) was added to each well. The plate was incubated on a 
plate shaker at 600 rpm in the dark at room temperature for 1 h. The plate 
was applied to a Multiscreen Vacuum Manifold (Millipore) and washed 
twice with 200 μl of wash buff  er. Streptavidin-phycoerythrin was diluted 
1:10 in wash buff  er, and 100 μl was added directly to each well. The plate 
was incubated on a plate shaker at 600 rpm in the dark at room temperature 
for 30 min. The plate was then applied to the vacuum manifold, washed 
twice, and each well was resuspended in 100 μl wash buff  er and shaken for 
1 min. The assay plate was then transferred to the Bio-Plex Luminex 100 
XYP instrument (Millipore) for analysis. Cytokine concentrations were cal-
culated using Bio-Plex Manager 3.0 software with a 5-parameter curve-
fi  tting algorithm applied for standard curve calculations.
Detection of STAT1 phosphorylation by fl  ow cytometry. The meth-
odology for the detection of P-STAT1 by fl  ow cytometry was adapted from 
that described by Lesinski et al. (39). Freshly isolated PBMCs, purifi  ed 
CD14+ monocytes, or monocyte-derived IDCs were treated with either 
mouse IgG1 isotype control antibody or the FcγRIIB blocking antibody. 
After a 1–24-h culture, the cells were labeled with the mouse anti–human 
phospho STAT1 antibody (clone pY701; BD Biosciences) as per the manu-
facturer’s protocol. In some experiments, cells were treated with 1,000 IU/ml 
IFN-α 2b (Schering-Plough). In some experiments, DCs or monocytes 
were pretreated with 10 μg/ml anti-IFNAR mAb (Fitzgerald Industries), 
10 μg/ml anti-IFN α antibody (clone MMHA-1; PBL Laboratories), 10 μg/ml 
anti–IFN-γ antibody (clone MMHG-1; PBL Laboratories), 10 μg/ml anti-
CD16 (clone 3G8; BD Biosciences), and 10 μg/ml antiCD32A (clone IV.3) 
or isotype controls.
Blocking inhibitory Fc𝗄R on human Mo-DCs and evaluation of 
their maturation. In brief, IDCs were harvested on day 5 of culture and 
treated with either 10 μg/ml anti–human FcγRIIB blocking antibody (clone 
2B6) or 10 μg/ml mouse IgG1 isotype control antibody (Sigma-Aldrich). 
After overnight culture, DCs were harvested to assess DC maturation. In 
some experiments, DCs were pretreated with 10 μg/ml CD16 blocking 
antibody (clone 3G8; BD Biosciences), and 10 μg/ml CD32A blocking anti-
body (clone IV.3) or isotype controls for 1 h before treatment with anti–human 
FcγRIIB blocking antibody. The following antibodies were used for evalu-
ating the surface changes associated with DC maturation: CD11c-APC, 
CD80-PE, CD83-FITC, CD86-PE, and HLA-DR-FITC (all obtained from 
Becton Dickinson).
Inhibition of STAT1 synthesis by RNA interference. CD14+ mono-
cytes were cultured in 1% plasma supplemented with IL4 and GMCSF on 
days 0 and 2, as described in Generation of DCs. On day 4, the IDCs were 
harvested, washed with Opti-MEM I medium without phenol red (Invitro-
gen) and resuspended in Opti-MEM I at a concentration of 2.5 × 107 cells/ml. 
4 × 106 IDCs were electroporated with 10 μg of STAT1 (siRNA; 
siGENOME SMARTpool; Thermo Fisher Scientifi  c) or nontargeting 
siRNA (siCONTROL Nontargeted siRNA; Thermo Fisher Scientifi  c) in a 
4-mm electroporation cuvette using the ECM830 Square Wave Electropor-
ator (Harvard Apparatus). The pulse conditions were a square wave pulse of 
500V and 0.5 ms. The electroporated DCs were immediately resuspended in 
complete medium (RPMI 1% plasma) supplemented with IL4 and GMCSF. 1368  FCγ RECEPTORS ENHANCE INTERFERON SIGNALING | Dhodapkar et al.
Inhibition of STAT1 protein was examined by Western blot analysis 2 and 
3 d after electroporation.
Western blot analysis to detect total and phosphorylated STAT1. 
Nonelectroporated DCs, as well as DCs electroporated with either nontar-
geting RNAi or STAT1 RNAi, were harvested, washed in PBS, and lysed 
with the radioimmunoprecipitation assay buff  er containing 150 mM NaCL, 
10 mM Tris, pH 7.2, 0.1% SDS, 1% Triton X-100, 1% deoxycholate, 5 mM 
EDTA, 100 mM sodium orthovanadate, and protease inhibitors (protease 
inhibitor cocktail tablet; Boehringer Mannheim). 25–50 μg of protein was 
resolved on a 7.5% polyacrylamide gel and transferred to a nitrocellulose 
membrane. Blots were probed with total STAT1 antibody (rabbit anti–
human STAT1, 1:1,000; Cell Signaling Technologies) overnight according 
to the manufacturers protocol. The membrane was treated with goat anti–
rabbit horseradish peroxidase secondary antibody (1:5,000; Southern Bio-
technology). Detection was done using the ECL plus Western blot detection 
reagents (GE Healthcare).
For the detection of phosphorylated STAT1 protein, IDCs were treated 
with mouse IgG1 isotype control antibody or anti-FcγRIIB antibody. 24 h 
later, the cells were harvested and lysed with the radioimmunoprecipitation 
assay buff  er containing 150 mM NaCL, 10 mM Tris, pH 7.2, 0.1% SDS, 1% 
Triton X-100, 1% deoxycholate, 5 mM EDTA, protease inhibitors, 10 mM 
sodium orthovanadate, and 10 mM β glycerol phosphate. Protein was re-
solved on a 7.5% polyacrylamide gel and transferred to a nitrocellulose 
membrane. Blots were probed with mAb specifi  c for phosphorylated STAT1 
(rabbit anti–human phospho-STAT1 antibody; 1:1,000, Cell Signaling 
Technologies) overnight, according to the manufacturers protocol. The 
membrane was treated with goat anti–rabbit horseradish peroxidase second-
ary antibody (1:5,000; Southern Biotechnology). Detection was done using 
the ECL plus Western blot detection reagents (GE Healthcare), and analyzed 
by quantitative densitometry using ImageJ software (W.S. Rasband, National 
Institutes of Health, Bethesda, MD; http://rsb.info.nih.gov/ij/). Data for 
P-STAT1 were fi  rst normalized against values for α-tubulin in that sample, 
before comparison to other samples.
Detection of DC maturation after STAT1 knockdown with the 
STAT1 RNAi. Nonelectroporated DCs or DCs electroporated with either 
STAT1 siRNA or nontargeting control siRNA were harvested 72 h after 
electroporation. DCs were treated with anti-FcγR antibody or mouse IgG1 
isotype control antibody. 24 h later, fl  ow cytometry was performed to exam-
ine the surface expression of CD83, CD80, and CD11c.
Online supplemental material. Table S1 shows a list of 95 genes that 
are diff  erentially expressed in DCs treated with anti-FcγRIIB antibody. 
Table S2 shows a list of genes up-regulated by more than fi  vefold at 24 h in 
immature Mo-DCs cultured in the presence of IFN-α2b (1,000 U/ml), 
compared with untreated DCs. The MIAME checklist for microarray analysis 
is presented as supplemental text.
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